Oxford Biomedica posted improved H1 results with a 10% revenue gain and 22 new client signings, though management acknowledged minor program delays and a £7.6 million impairment charge.
Revenue and EBITDA improved while guidance was maintained, but an impairment charge and client deferrals introduce mixed signals.
Oxford Biomedica reported a 10% revenue increase to £80.2 million for the first half of 2026, driven by a 20% surge in manufacturing activity. Despite narrowing EBITDA losses, the company recorded a £7.6 million impairment charge at its French site and noted client-driven program deferrals. Management reiterated its 2026 revenue guidance of £180 million–£200 million and remains committed to long-term growth targets.
The company recorded a £7.6 million impairment charge on its French site due to lower near-term revenue expectations at that location.
Management reiterated its 2026 guidance of £180 million–£200 million and maintains its ambition to reach approximately £500 million in revenue by 2030.